IRIS
DE LUCA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.972
NA - Nord America 2.875
EU - Europa 2.513
SA - Sud America 773
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.188
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.768
SG - Singapore 1.167
CN - Cina 938
RO - Romania 699
BR - Brasile 663
SE - Svezia 468
IT - Italia 451
HK - Hong Kong 423
DE - Germania 255
VN - Vietnam 179
RU - Federazione Russa 141
FI - Finlandia 105
GB - Regno Unito 89
CA - Canada 62
AT - Austria 57
FR - Francia 53
AR - Argentina 51
IN - India 51
NL - Olanda 48
JP - Giappone 45
PL - Polonia 37
MX - Messico 35
ES - Italia 26
ZA - Sudafrica 25
TR - Turchia 23
ID - Indonesia 22
PH - Filippine 20
BD - Bangladesh 19
EC - Ecuador 18
LT - Lituania 16
UA - Ucraina 14
UZ - Uzbekistan 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
IE - Irlanda 10
IQ - Iraq 10
PK - Pakistan 10
PY - Paraguay 10
CO - Colombia 9
BE - Belgio 8
KR - Corea 8
IR - Iran 7
PE - Perù 7
EG - Egitto 6
NO - Norvegia 6
AZ - Azerbaigian 5
LU - Lussemburgo 5
MK - Macedonia 5
TN - Tunisia 5
BH - Bahrain 4
MA - Marocco 4
XK - ???statistics.table.value.countryCode.XK??? 4
BG - Bulgaria 3
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IL - Israele 3
KZ - Kazakistan 3
PT - Portogallo 3
CH - Svizzera 2
EU - Europa 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
JO - Giordania 2
LV - Lettonia 2
MY - Malesia 2
SA - Arabia Saudita 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
CZ - Repubblica Ceca 1
GA - Gabon 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
LB - Libano 1
MD - Moldavia 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
UY - Uruguay 1
Totale 9.188
Salva come PNG Salva come JPEG
Città #
Dallas 1.096
Singapore 582
Hong Kong 420
Ashburn 304
Shanghai 247
Beijing 166
Hefei 156
New York 136
Milan 119
Lawrence 99
Princeton 99
Munich 96
Los Angeles 91
Ho Chi Minh City 72
Moscow 72
São Paulo 70
Boardman 63
Nuremberg 61
Helsinki 59
Rome 39
Tokyo 35
Warsaw 33
Hanoi 29
Atlanta 28
Montreal 27
Rio de Janeiro 27
Turku 27
Denver 26
Santa Clara 25
Cesano Boscone 23
Frankfurt am Main 22
Guangzhou 22
Johannesburg 21
Poplar 21
Chicago 19
Falkenstein 19
Stockholm 19
Chennai 18
Lappeenranta 18
Vienna 17
Ankara 15
Brooklyn 15
Mexico City 15
London 13
Seattle 13
Amsterdam 12
Houston 12
Orem 12
The Dalles 12
Boston 11
Buffalo 11
Campinas 11
Secaucus 11
Belo Horizonte 10
City of London 10
Dublin 10
Haiphong 10
Manchester 10
Naples 10
Phoenix 10
Shenzhen 10
Tashkent 10
Tianjin 10
Xi'an 10
Makati City 9
Mumbai 9
Toronto 9
Brasília 8
Brussels 8
Porto Alegre 8
Seongnam-si 8
Verona 8
Can Tho 7
Curitiba 7
Guayaquil 7
Marília 7
Padua 7
Pune 7
San Francisco 7
Ancona 6
Biên Hòa 6
Columbus 6
Hangzhou 6
Istanbul 6
Lima 6
Manaus 6
Natal 6
New Delhi 6
Osaka 6
Oslo 6
Recife 6
Romagnano Sesia 6
Roubaix 6
San Jose 6
Zhengzhou 6
Baghdad 5
Baie-D'Urfé 5
Baku 5
Brescia 5
Dronten 5
Totale 5.033
Salva come PNG Salva come JPEG
Nome #
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 417
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 380
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 325
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 319
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 207
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 160
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 131
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 107
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 106
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 106
B cells in systemic sclerosis: A possible target for therapy 98
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 94
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 94
Arrhythmias in Myocarditis: State of the Art 85
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 85
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 79
C3-glomerulopathy and MGUS: The skin beyond the kidney 79
A Novel Histiocytosis With Synovial and Skin Involvement 79
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 79
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 78
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 78
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 77
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 77
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 76
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 76
Pruritus characteristics in a large Italian cohort of psoriatic patients 74
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 73
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 73
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 72
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 72
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 71
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 70
Advances in potential targeted therapies for Erdheim-Chester disease 70
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 69
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 69
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 67
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 66
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 66
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 65
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 65
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 65
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 65
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 65
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 64
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 64
Drug retention rates of biological agents in adult onset Still's disease 64
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 64
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 63
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 63
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 62
Therapeutic strategies for primary heart involvement in systemic sclerosis 61
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 61
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 61
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 61
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 60
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 59
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 59
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 58
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 57
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 57
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 57
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 57
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 56
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 56
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 56
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 55
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 55
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 55
Cardiovascular magnetic resonance parametric mapping in the risk stratification of patients affected by chronic myocarditis 53
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 52
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 52
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 51
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 51
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 51
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic 51
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 50
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 49
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 49
Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation 49
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 49
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 49
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 48
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 48
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 48
Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report 46
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 46
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 46
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 45
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 45
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 43
Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging 43
Therapeutic strategies for virus-negative myocarditis: a comprehensive review 42
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 42
Pain and Frailty in Hospitalized Older Adults 41
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 41
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 41
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 41
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 41
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review 40
Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis 40
Totale 7.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.059
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.059
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 12 8 3 1 0 4 2
2021/2022249 1 0 102 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024744 25 56 75 67 65 111 42 82 5 33 36 147
2024/20253.364 224 41 102 104 130 218 1.093 331 388 233 200 300
2025/20264.342 612 868 944 1.147 707 64 0 0 0 0 0 0
Totale 9.570